The consensus among 1 Wall Street analyst covering (NASDAQ: CLVS) stock is to Buy CLVS stock.
Similarly, Will Clovis Oncology be bought?
Nothing has changed since our initial recommendation in January 2020 and the benefit/risk ration of this share is still excellent. With a stock price of around $5.80 and a market cap of $509 million, Clovis Oncology remains one of the top takeover target and buyout candidate for 2021.
Why is Clvs stock going down? Biotechnology investors are familiar with Clovis Oncology (NASDAQ:CLVS). The company’s stock is beaten down (down over 90% from the 2017 high) after the company lost the PARP inhibitor race to competition like AstraZeneca (AZN) and sales of its PARP inhibitor Rubraca did not meet analyst expectations.
Thereof, Is Clvs a shorted stock?
Short Shares Availability
This table shows the number of shares of US:CLVS available to be shorted at a leading prime brokerage. It is not the total number of shares available to short, nor is it the short interest.
Will Clvs stock go up?
During the day the stock fluctuated 17.49% from a day low at $2.63 to a day high of $3.09. The price has risen in 6 of the last 10 days and is up by 75% over the past 2 weeks.
…
Predicted Opening Price for Clovis Oncology of Tuesday, April 5, 2022.
| Fair opening price April 5, 2022 | Current price |
|---|---|
| $2.82 | $2.73 (Undervalued) |
Who owns Clvs?
Top 10 Owners of Clovis Oncology Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| The Vanguard Group, Inc. | 6.90% | 9,820,571 |
| BlackRock Fund Advisors | 5.82% | 8,284,149 |
| Palo Alto Investors LP | 2.81% | 3,997,826 |
| Geode Capital Management LLC | 1.56% | 2,212,612 |
Why is Clovis Oncology so low?
Clovis Oncology: The short thesis might be overdone
Over the prior 36 months, Clovis’ stock price has dropped by approximately 90%. The biotech’s inability to turn its Poly ADP-ribose Polymerase (PARP) inhibitor Rubraca into a viable growth product is the core reason behind this downward trend.
What is the short interest on Clvs?
Clovis Oncology currently has a short interest ratio of 6.0. Learn More on Clovis Oncology’s short interest ratio.
Should I invest in Clovis Oncology?
There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should « buy » Clovis Oncology stock. View analyst ratings for Clovis Oncology or view top-rated stocks.
Is Clovis Oncology a good company?
Clovis Oncology has an overall rating of 3.6 out of 5, based on over 35 reviews left anonymously by employees. 47% of employees would recommend working at Clovis Oncology to a friend and 35% have a positive outlook for the business. This rating has improved by 8% over the last 12 months.
What does Clovis Oncology do?
Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.
How much is Clvs shorted?
Short Interest: CLVS (NASDAQ)
| Clovis Oncology Incorporated | $ 2.65 |
|---|---|
| CLVS (NASDAQ) | -0.14 |
When did Clovis Oncology go public?
In addition, the underwriters have a 30-day option to purchase up to an additional 1,500,000 shares of common stock from Clovis Oncology to cover over-allotments, if any. Shares of Clovis Oncology’s common stock will trade on the NASDAQ Global Select Market under the symbol « CLVS » beginning on November 16, 2011.
Who is the CEO of Clovis Oncology?
President/CEO/Co-Founder, Clovis Oncology Inc.
Who founded Clovis Oncology?
Clovis Oncology is an American pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado.
…
Clovis Oncology.
| Type | Public |
|---|---|
| Founder | Patrick Mahaffy |
| Headquarters | Boulder, Colorado , U.S. |
| Revenue | $165 Million(2020) |
| Number of employees | 429 |
Join TheMoney.co community and don’t forget to share this post !